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Purpose: To investigate the relationship between rising patterns of prostate-specific 
antigen (PSA) before chemotherapy and PSA flare during the early phase of chemo-
therapy in patients with castration-resistant prostate cancer (CRPC). Materials and 
Methods: This study included 55 patients with CRPC who received chemotherapy 
and in whom pre-treatment or post-treatment PSA levels could be serially obtained. 
The baseline parameters included age, performance, Gleason score, PSA level, and 
disease extent. PSA doubling time was calculated using the different intervals: the 
conventional interval from the second hormone manipulation following the nadir 
until anti-androgen withdrawal (PSADT1), the interval from the initial rise after an-
ti-androgen withdrawal to the start of chemotherapy (PSADT2), and the interval 
from the nadir until the start of chemotherapy (PSADT3). The PSA growth patterns 
were analyzed using the ratio of PSADT2 to PSADT1. Results: There were two 
growth patterns of PSA doubling time: 22 patients (40.0%) had a steady pattern with 
a more prolonged PSADT2 than PSADT1, while 33 (60.0%) had an accelerating 
pattern with a shorter PSADT2 than PSADT1. During three cycles of chemothera-
py, PSA flare occurred in 11 patients (20.0%); of these patients, 3 were among 33 
(9.1%) patients with an accelerating PSA growth pattern and 8 were among 22 pa-
tients (36.4%) with a steady PSA growth pattern (p=0.019). Multivariate analysis 
showed that only PSA growth pattern was an independent predictor of PSA flare 
(p=0.034). Conclusion: An exponential rise in PSA during anti-androgen withdraw-
al is a significant predictor for PSA flare during chemotherapy in CRPC patients.
Key Words:   Prostate cancer, castration-resistant, prostate-specific antigen, pros-
tate-specific antigen doubling time, prostate-specific antigen flare
INTRODUCTION
Prostate cancer is the most common cancer in Western countries, and its incidence 
has been rapidly rising in Asia.1-4 Androgen deprivation therapy treats advanced 
prostate cancer effectively for a considerable amount of time; however, most pa-
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MATERIALS AND METHODS
Study sample
From 2002 to 2008, 98 patients with CRPC received sys-
temic chemotherapy at our institution. Of them, the patients 
who had been followed up from the start of androgen depri-
vation therapy until 3 months after chemotherapy were in-
cluded in this study. We excluded patients who did not un-
dergo anti-androgen withdrawal before chemotherapy and 
those for whom serum PSA levels were not measured. Ulti-
mately, a total of 55 patients were assessed in this study. 
Chemotherapy continued until disease progression, uncon-
trolled toxicity, or deterioration of performance occurred. 
The Institutional Review Board of our institution approved 
the execution of this retrospective study.
Calculation of PSA doubling time
PSA doubling time was calculated using the log slope meth-
od.18 Briefly, the PSA rate variable was calculated by taking 
the natural log of each PSA measurement, plotting the results 
versus time, and then measuring the slope of the linear re-
gression through the data points ln [PSAt]=ln [PSAinitial]+mt 
(t=time). PSADT was then calculated by dividing ln 2 by 
m.18 PSADT1 was defined as PSA doubling time calculated 
with the traditional interval from the first rise greater than the 
nadir during androgen deprivation therapy until androgen 
withdrawal. PSADT2 was defined as the PSA doubling time 
from the initial rise after anti-androgen withdrawal until the 
start of chemotherapy (Fig. 1). PSADT3 was defined as the 
PSA doubling time during the total interval from the nadir 
until the start of chemotherapy. The ratios of PSA doubling 
times were analyzed using the ratio of PSADT1 to PSADT2 
(Fig. 1).
Definition of PSA flare 
PSA flare was defined as a pattern of serum PSA level ini-
tially rising after the start of chemotherapy and then falling 
below the baseline prechemotherapy PSA level within 12 
weeks.
Data collection
The baseline parameters included patient age, performance 
status (Karnofsky score), serum PSA level, Gleason score, 
extent of disease, and previous treatments. The end point of 
this study was an occurrence of PSA flare after the start of 
chemotherapy.
tients with the disease eventually progress to castration-re-
sistant prostate cancer (CRPC), which is refractory to any 
hormone manipulation.5 CRPC remains the main cause of 
prostate cancer‒related mortality. Recently, randomized trials 
with docetaxel-based chemotherapy reported a significant 
improvement in overall survival in patients with CRPC.6 
Since then, systemic chemotherapy has become the stan-
dard first-line treatment in the management of CRPC.7,8
As most CRPC patients have non-measurable skeletal 
metastases, response assessment during chemotherapy gen-
erally relies on a traditional serum marker, prostate-specific 
antigen (PSA). However, PSA is occasionally inaccurate 
when assessing disease status in advanced prostate cancer, 
as poorly differentiated advanced prostate cancer may not 
produce PSA.9,10 Recent studies have reported the existence 
of PSA flare phenomenon after the onset of chemotherapy 
in patients with CRPC.11-16 PSA flare is not related with pro-
gression and does not impact outcomes negatively. Howev-
er, considering that there has been no predictor for an occur-
rence of PSA flare in CRPC patients, an inefficient treatment 
must be maintained for more than 12 weeks.9,11,13,16
Changes in PSA over time (i.e., PSA dynamics) have 
been advocated for risk stratification of prostate cancer 
across the spectrum of the disease.17 PSA doubling time 
represents the relative rate of PSA change over time and is 
defined as the time needed for the PSA value to double; it 
also takes into account the exponential nature of neoplastic 
growth and thus requires logarithmic analysis.18 To date, 
PSA doubling time has emerged as a potentially useful tool 
in predicting the prognosis of patients with CRPC. Howev-
er, there has been no study to investigate this calculation as 
a pretreatment predictor for an occurrence of PSA flare dur-
ing chemotherapy.
PSA doubling time is generally calculated using the peri-
od from the nadir until the start of the next treatment, usual-
ly anti-androgen withdrawal.17,18 However, although PSA 
increases after the next hormonal manipulation until the 
start of chemotherapy, the values during this period are not 
included in the calculation of PSA doubling time. We pos-
tulated that PSA changes immediately before chemothera-
py may be associated with PSA changes immediately after 
chemotherapy and subsequently focused on the interval of 
antiandrogen withdrawal, the final interval immediately be-
fore the start of chemotherapy in patients with CRPC. In 
this study, we report the relationship between pretreatment 
PSA doubling time during antiandrogen withdrawal and 
PSA flare after chemotherapy.
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IL, USA). All tests were two-sided and performed at the 
5% significance level. 
RESULTS
 
Patient characteristics
Patient characteristics of the study sample are summarized in 
Table 1. The median age was 69 years old (range, 54 to 84), 
and the median follow-up period from the start of chemo-
therapy was 13.5 months (range, 3.0 to 47.0). Most patients 
(91.0%) had a good performance score at the start of chemo-
therapy. There was no mortality within the 3 months after the 
start of chemotherapy. During three cycles of docetaxel che-
motherapy, PSA flare occurred in 11 patients (20.0%). After 
the PSA flare, the PSA level declined to the level of response 
in 3 patients (27.3%) and to the level of stabilization in 8 pa-
tients (72.7%). 
PSA doubling times
Table 2 shows the mean and median values of PSA dou-
bling times using different intervals for the 55 patients. Us-
ing the conventional PSA doubling time interval, the mean 
was 3.61 months, and the median was 2.37 months. In con-
trast, the mean and median values of the PSA doubling time 
during anti-androgen withdrawal were 2.42 months and 
1.76 months, respectively. The mean and median PSADT2 
values were shorter than the mean and median values for 
both PSADT1 and PSADT3. As for the ratio of PSADT2 to 
Statistical considerations
For univariate analysis, the Mann-Whitney U test was used 
to compare the median values of the two groups, and the 
chi-square test and Fisher’s exact test were used to compare 
binominal variables. Logistic regression analysis was used 
in the multivariate analysis. Statistical analyses were per-
formed using the Statistical Package for Social Sciences 
(SPSS), version 17.0, for Windows (SPSS Inc., Chicago, 
Fig. 1. Schematic graph of PSA doubling times according to different intervals during the transient period from the diagnosis of CRPC until 
the end of anti-androgen withdrawal and PSA response during docetaxel chemotherapy. PSA, prostate-specific antigen; PSADT1, PSA 
doubling time calculated with the traditional interval from the first rise greater than the nadir during androgen deprivation therapy until 
androgen withdrawal; PSADT2, PSA doubling time from the initial rise after anti-androgen withdrawal until the start of chemotherapy; 
PSADT3, PSA doubling time during the total interval from the nadir until the start of chemotherapy.
Table 1. Baseline Patient Characteristics
Variables Original study population
No. of patients 55
Age (yrs)
    Median (range)    69 (54‒84)
Karnofsky performance score (%)  
    90% 22 (40.0)
    80% 28 (50.9)
    70% 5 (9.1)
Gleason score (%)
    ≥8 44 (83.6)
    ≤7 5 (9.1)
    Missing 4 (7.3)
Median PSA (ng/mL)
    At initial diagnosis 252.8 (3.5‒12467.0)
    At nadir 2.29 (0.05‒262.0)
    Before chemotherapy     53.6 (2.17‒75000.0)
Disease Extents (%)
    No metastasis 3 (5.4)
    Lymph node metastasis only 4 (7.3)
    Distant metastasis 48 (87.3)
PSA, prostate-specific antigen.
PSA progression
PSA flare
PSA response
GnRH agonist+antiandrogen Antiandrogen withdrawal Docetaxel
PSADT1
PSADT3
PSADT2
PS
A 
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patients (9.1%) in whom PSADT2 was longer than PSADT1 
experienced PSA flare. Multivariate logistic regression analy-
sis also revealed that ratio of PSA doubling time was inde-
pendently associated with an occurrence of PSA flare during 
chemotherapy (odds ratio=24.618; p=0.034) (Table 5). 
DISCUSSION
The PSA flare often observed during the early phase of che-
motherapy suggests that PSA monitoring is occasionally in-
appropriate for evaluating the response of prostate cancer 
during the early phase of chemotherapy.9 Prediction of this 
phenomenon has an important implication in selecting the 
proper management of CRPC. Variations in PSA levels im-
mediately before chemotherapy may be closely associated 
PSADT1, PSADT2 was shorter than PSADT1 in 33 patients 
(60.0%) and longer than PSADT1 in 22 patients (40.0%). 
Univariate and multivariate analyses
In univariate analyses with baseline clinical parameters, no 
clinical factors were associated with an occurrence of PSA 
flare after chemotherapy (Table 3). PSA flare occurred in 9 of 
29 patients who received docetaxel-based chemotherapy, 
while it occurred in only 2 of 26 patients who received estra-
mustine-based chemotherapy. In univariate analyses with 
PSA parameters, pretreatment PSA and PSA doubling times 
were not associated with an occurrence of PSA flare; howev-
er, the ratio of PSA doubling time (PSADT2 to PSADT1) 
was associated with PSA flare (p=0.019) (Table 3 and 4). 
PSA flare occurred in 8 of 22 patients (36.4%) in whom 
PSADT2 was shorter than PSADT1; conversely, only 3 of 33 
Table 2. Pretreatment PSA Doubling Time Values Using Different Intervals in the Calculation and Ratio of PSA Doubling Times
Variables Mean SD Median Range
PSADT1 (mons) 3.61 4.62 2.37   0.25‒27.58
PSADT2 (mons) 2.42 2.13 1.76   0.06‒12.46
PSADT3 (mons) 3.11 1.99 2.51 0.25‒9.29
PSADT2/PSADT1 1.18 1.32 0.75 0.01‒6.70
PSA doubling time was calculated using the log slope method.14 Briefly, the PSA rate variable was calculated by taking the natural log of each PSA 
measurement, plotting them versus time and then measuring the slope of the linear regression through the data points ln [PSAt]=ln [PSAinitial]+mt (t=time). 
PSADT was then calculated by dividing ln 2 by m.14 PSADT1, PSA doubling time calculated using the conventional interval from the first rise greater than 
the nadir during androgen deprivation therapy until the start of the next treatment; PSADT2, PSA doubling time calculated using the period from the initial 
rise after anti-androgen withdrawal until the start of chemotherapy; PSADT3, PSA doubling time calculated using the total period from the first rise greater 
than the nadir during androgen deprivation therapy until the start of chemotherapy; PSADT2/PSADT1, the ratio of PSADT2 to PSADT1; SD, standard devia-
tion; PSA, prostate-specific antigen.
Table 3. Univariate Analyses of Pretreatment Binomial Variables for Occurrences of PSA Flare during Chemotherapy in Pa-
tients with CRPC
Variables No. patients PSA flare (%) p value
Age 1.000*
    <65 14   3 (21.4)
    >65 41   8 (27.3)
Performance score (%) 0.886*
    90% 23   4 (17.4)
    80% 27   6 (22.2)
    70%   5   1 (20.0)
Gleason score (%)   0.572*
    ≤7   5   2 (40.0)
    ≥8 46   9 (19.6)
Disease Extents 1.000*
    No metastasis   7   1 (14.3)
    Distant metastasis 48 10 (20.8)
Ratio of PSA doubling time 0.019*
    ≥1 33 3 (9.1)  
    <1 22   8 (36.4)  
PSA, prostate-specific antigen; CRPC, castration-resistant prostate cancer.
*Fisher’s exact test.
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tial growth. However, during anti-androgen withdrawal, 
60% of patients experienced a shortening of PSA doubling 
time, whereas 40% experienced a prolonging of PSA dou-
bling time. This difference was significantly correlated with 
the occurrence of the PSA flare phenomenon during the ini-
tial phase of chemotherapy on the basis of multivariate 
analysis. 
Only limited information is available regarding PSA flare 
during the early phase of chemotherapy.19 PSA flare associ-
ated with luteinizing hormone-releasing hormone (LHRH) 
agonist is a well-known phenomenon; however, PSA flare 
during chemotherapy differs in several aspects.19 In contrast 
with PSA flare during LHRH agonist therapy, which is re-
lated to the transient increase in testosterone levels, PSA 
flare during chemotherapy is generally not related with tes-
tosterone levels or clinical symptoms and is not associated 
with survival outcomes in CRPC patients.12,13,16,19 PSA flare 
after chemotherapy appears not to be related with overall 
disease progression. From our results, pretreatment risk as-
with PSA level changes during the early phase of chemo-
therapy. In this study, we focused on the relationship be-
tween the variation patterns of PSA levels immediately be-
fore chemotherapy and those after chemotherapy in patients 
with CRPC. To our knowledge, this is the first study to dem-
onstrate a pretreatment predictor for PSA flare during che-
motherapy in patients with CRPC.
PSA changes after anti-androgen withdrawal are usually 
not included in the conventional calculation of PSA dou-
bling time.16,17 However, we assessed an additional PSA 
doubling time that was calculated using the PSA values 
during this period and then used the ratio of two different 
PSA doubling times to evaluate the PSA growth pattern 
during the period from nadir to chemotherapy. In this study, 
PSA doubling time after anti-androgen withdrawal was dif-
ferent from the conventional PSA doubling time in a signif-
icant proportion of patients. It is possible that the latter PSA 
doubling time is shorter than the former PSA doubling time, 
as the progression of prostate cancer is based on exponen-
Table 4. Univariate Logistic Regression Analyses of Pretreatment Continuous Variables for Occurrences of PSA Flare during 
Chemotherapy in Patients with CRPC
Variables Odd ratio 95% CI p value
PSA (ng/mL)
    At initial diagnosis 1.000 1.000‒1.000 0.339
    At nadir 1.002 0.988‒1.016 0.794
    Before chemotherapy 1.000 1.000‒1.000 0.750
PSA doubling time
    PSADT1 0.904 0.695‒1.176 0.453
    PSADT2 0.995 0.726‒1.363 0.974
    PSADT3 1.118 0.813‒1.538 0.493
Ratio of PSA doubling time 1.014 0.616‒1.669 0.958
PSA, prostate-specific antigen; CRPC, castration-resistant prostate cancer; CI, confidence interval; PSADT1, PSA doubling time calculated using the 
conventional interval from the first rise greater than the nadir during androgen deprivation therapy until the start of the next treatment; PSADT2, PSA 
doubling time calculated using the period from the initial rise after anti-androgen withdrawal until the start of chemotherapy; PSADT3, PSA doubling time 
calculated using the total period from the first rise greater than the nadir during androgen deprivation therapy until the start of chemotherapy; ratio of PSA 
doubling time, PSADT2/ PSADT1.
Table 5. Multivariate Logistic Regression Analysis for Occurrences of PSA Flare during Chemotherapy in Patients with CRPC
Variables Odd ratio 95% CI p value
PSA at initial diagnosis   1.000 1.000‒1.001 0.750
Disease extent
    No metastasis Reference - -
    Distant metastasis   5.068     0.196‒130.872 0.328
Ratio of PSA doubling time
    ≥1 Reference - -
    <1 24.618     1.282‒472.586 0.034
PSA, prostate-specific antigen; CRPC, castration-resistant prostate cancer; CI, confidence interval; PSADT1, PSA doubling time calculated using the con-
ventional interval from the first rise greater than the nadir during androgen deprivation therapy until the start of the next treatment; PSADT2, PSA doubling 
time calculated using the period from the initial rise after anti-androgen withdrawal until the start of chemotherapy; ratio of PSA doubling time, PSADT2/
PSADT1.
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CRPC contains more heterogeneous tumor cell popula-
tions than androgen-sensitive prostate cancer in terms of 
androgen independence and PSA production.20 Highly met-
astatic prostate cancer cells are poorly differentiated and are 
usually less capable of producing PSA.10,20 After the acqui-
sition of androgen independence, prostate cancer cells may 
be changed to tumor cells with different characteristics. Time 
to response with chemotherapy can also differ according to 
tumor cell characteristics. Differences in the proportion of 
tumor cell populations related to PSA production can result 
in different levels of initial PSA after the initiation of chemo-
therapy, regardless of overall response. A transient increase in 
PSA after the initiation of chemotherapy can reflect a rela-
tively dominant acquisition of the tumor cell population, 
which delays the response to chemotherapy after the acqui-
sition of androgen independence. Hence, the characteristics 
of tumor cells are not stable over time. However, current 
calculation methods for PSA doubling time do not reflect 
different tumor characteristics, as dynamic changes in sev-
eral PSA values are averaged into one slope for the PSA 
doubling time. Therefore, comparison of PSA doubling time 
using an alternative calculation for PSA doubling time after 
anti-androgen withdrawal can be a suitable method for show-
ing the changing characteristics of CRPC within a patient 
before chemotherapy during the period from nadir to the 
start of chemotherapy. 
In summary, PSA doubling time after anti-androgen with-
drawal is a useful tool for evaluating the characteristics of 
tumor progression of CRPC before chemotherapy, and com-
parison of this alternative PSA doubling time with conven-
tional PSA doubling time is a significant pretreatment pa-
rameter for predicting an occurrence of PSA flare after the 
early phase of chemotherapy. However, due to the limita-
tions of the retrospective nature of this study and the small 
cohort, a prospective study with a larger cohort is required 
to confirm our results. 
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